机构：[1]Organoid Research Center, Xiamen Broad Creation Biomedical Institute, Xiamen, China[2]Institute of Neuroscience, School of Medicine, Xiamen University, Xiamen, China[3]Department of General Surgery, Xiamen Branch, Zhongshan Hospital, Fudan University, Xiamen, China,[4]Oncology Department, Xiamen Haicang Hospital, Xiamen, China[5]Department of Obstetrics and Gynecology, Xiamen Branch, Zhongshan Hospital, Fudan University, Xiamen, China[6]Central Lab, The Fifth Hospital of Xiamen, Xiamen, China[7]Department of Traditional Chinese Medicine, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China临床科室中医科河北医科大学第四医院[8]Department of Interventional Oncology, Renji Hospital School of Medicine, Shanghai Jiaotong University, Shanghai, China
Human gastrointestinal cancer (e.g., gastric cancer and colorectal cancer) has been a leading cause of cancer-related deaths worldwide and has imposed a great threat to the public health. Although early-stage gastrointestinal cancer can be effectively treated by surgery, followed by postoperative chemotherapy, patients with advanced gastrointestinal cancer often exhibit poor prognosis and cancer relapse due to the absence of effective personalized treatment strategies. Patient-derived cancer organoid technology has been rapidly developed in recent years, and its emergence has opened up an unprecedented approach to model human cancers in vitro. Patient-derived cancer organoids involve the ex vivo culture of fragments of freshly resected human tumors that retain the histological features of original tumors. This review thoroughly discussed the evolutionary process of human gastrointestinal organoids cultured since 2009, and highlighted the potentials of patient-derived cancer organoids in clinical management of gastrointestinal cancer in terms of advances achieved in cancer modelling compared with conventional modelling methods, high-throughput drug screening, and development of personalized treatment selection. Additionally, the current limitations of patient-derived cancer organoids and the potential solutions to overcome these problems were summarized.</p>
第一作者机构：[1]Organoid Research Center, Xiamen Broad Creation Biomedical Institute, Xiamen, China
共同第一作者：
通讯作者：
通讯机构：[1]Organoid Research Center, Xiamen Broad Creation Biomedical Institute, Xiamen, China[8]Department of Interventional Oncology, Renji Hospital School of Medicine, Shanghai Jiaotong University, Shanghai, China
推荐引用方式(GB/T 7714)：
Zhang Ruobing,Guo Tiantian,Ji Lulin,et al.Development and Application of Patient-Derived Cancer Organoidsin Clinical Management of Gastrointestinal Cancer: A State-of-the-Art Review[J].FRONTIERS IN ONCOLOGY.2021,11:doi:10.3389/fonc.2021.716339.
APA：
Zhang, Ruobing,Guo, Tiantian,Ji, Lulin,Yin, Yirui,Feng, Shuitu...&Zeng, Fanwei.(2021).Development and Application of Patient-Derived Cancer Organoidsin Clinical Management of Gastrointestinal Cancer: A State-of-the-Art Review.FRONTIERS IN ONCOLOGY,11,
MLA：
Zhang, Ruobing,et al."Development and Application of Patient-Derived Cancer Organoidsin Clinical Management of Gastrointestinal Cancer: A State-of-the-Art Review".FRONTIERS IN ONCOLOGY 11.(2021)
